AstraZeneca has agreed an up-to-$1.86bn collaboration with machine-learning biotech Insitro to use AI to discover treatments for fatty liver and myocardial disease. AstraZeneca will pay a $40m upfront fee. Insitro will combine its and AstraZeneca’s data to study disease mechanisms; if successful, Insitro could receive up to $1.46bn in additional payments plus potential royalties on any drugs. California-based Insitro has prior drug-development deals with Eli Lilly and Bristol Myers Squibb and is

AstraZeneca has agreed an up-to-$1.86bn collaboration with machine-learning biotech Insitro to use AI to discover treatments for fatty liver and myocardial disease. AstraZeneca will pay a $40m upfront fee. Insitro will combine its and AstraZeneca’s data to study disease mechanisms; if successful, Insitro could receive up to $1.46bn in additional payments plus potential royalties on any drugs. California-based Insitro has prior drug-development deals with Eli Lilly and Bristol Myers Squibb and is backed by Andreessen Horowitz, BlackRock and Temasek.